Annual CFF
$122.24 M
+$121.13 M+10883.02%
December 31, 2024
Summary
- As of March 13, 2025, ITOS annual cash flow from financing activities is $122.24 million, with the most recent change of +$121.13 million (+10883.02%) on December 31, 2024.
- During the last 3 years, ITOS annual CFF has risen by +$118.58 million (+3240.83%).
- ITOS annual CFF is now -64.08% below its all-time high of $340.34 million, reached on December 31, 2020.
Performance
ITOS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$285.00 K
+$727.00 K+164.48%
December 31, 2024
Summary
- As of March 13, 2025, ITOS quarterly cash flow from financing activities is $285.00 thousand, with the most recent change of +$727.00 thousand (+164.48%) on December 31, 2024.
- Over the past year, ITOS quarterly CFF has increased by +$727.00 thousand (+164.48%).
- ITOS quarterly CFF is now -99.87% below its all-time high of $212.87 million, reached on September 30, 2020.
Performance
ITOS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$122.24 M
-$22.00 K-0.02%
December 31, 2024
Summary
- As of March 13, 2025, ITOS TTM cash flow from financing activities is $122.24 million, with the most recent change of -$22.00 thousand (-0.02%) on December 31, 2024.
- Over the past year, ITOS TTM CFF has dropped by -$22.00 thousand (-0.02%).
- ITOS TTM CFF is now -64.08% below its all-time high of $340.34 million, reached on December 31, 2020.
Performance
ITOS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ITOS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +164.5% | -0.0% |
| 3 y3 years | +3240.8% | -87.9% | +3240.8% |
| 5 y5 years | +442.4% | +100.0% | +442.4% |
ITOS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -99.8% | +164.5% | -0.4% | >+9999.0% |
| 5 y | 5-year | -64.1% | >+9999.0% | -99.9% | +125.8% | -64.1% | >+9999.0% |
| alltime | all time | -64.1% | >+9999.0% | -99.9% | +125.8% | -64.1% | -100.0% |
ITeos Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $122.24 M(>+9900.0%) | $285.00 K(-164.5%) | $122.24 M(-0.0%) |
| Sep 2024 | - | -$442.00 K(-100.4%) | $122.26 M(-0.4%) |
| Jun 2024 | - | $122.38 M(>+9900.0%) | $122.72 M(>+9900.0%) |
| Mar 2024 | - | $22.00 K(-92.8%) | $557.00 K(-50.0%) |
| Dec 2023 | $1.11 M(-43.9%) | $307.00 K(+2970.0%) | $1.11 M(-48.9%) |
| Sep 2023 | - | $10.00 K(-95.4%) | $2.18 M(+0.5%) |
| Jun 2023 | - | $218.00 K(-62.3%) | $2.17 M(-2.7%) |
| Mar 2023 | - | $578.00 K(-57.9%) | $2.23 M(+12.3%) |
| Dec 2022 | $1.98 M(-45.8%) | $1.37 M(<-9900.0%) | $1.98 M(-33.1%) |
| Sep 2022 | - | -$1000.00(-100.4%) | $2.97 M(-13.0%) |
| Jun 2022 | - | $278.00 K(-16.5%) | $3.41 M(+2.5%) |
| Mar 2022 | - | $333.00 K(-85.9%) | $3.33 M(-9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $3.66 M(-98.9%) | $2.36 M(+434.2%) | $3.66 M(+71.3%) |
| Sep 2021 | - | $441.00 K(+126.2%) | $2.14 M(-99.0%) |
| Jun 2021 | - | $195.00 K(-70.8%) | $214.57 M(+0.6%) |
| Mar 2021 | - | $667.00 K(-19.9%) | $213.27 M(-37.3%) |
| Dec 2020 | $340.34 M(+1410.0%) | $833.00 K(-99.6%) | $340.34 M(+0.2%) |
| Sep 2020 | - | $212.87 M(<-9900.0%) | $339.51 M(+168.0%) |
| Jun 2020 | - | -$1.11 M(-100.9%) | $126.70 M(-15.7%) |
| Mar 2020 | - | $127.74 M(>+9900.0%) | $150.28 M(+566.7%) |
| Dec 2019 | $22.54 M(-4.1%) | $0.00(-100.0%) | $22.54 M(0.0%) |
| Sep 2019 | - | $65.00 K(-99.7%) | $22.54 M(+0.3%) |
| Jun 2019 | - | $22.47 M(>+9900.0%) | $22.47 M(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $23.51 M | - | - |
FAQ
- What is iTeos Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for iTeos Therapeutics?
- What is iTeos Therapeutics annual CFF year-on-year change?
- What is iTeos Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for iTeos Therapeutics?
- What is iTeos Therapeutics quarterly CFF year-on-year change?
- What is iTeos Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for iTeos Therapeutics?
- What is iTeos Therapeutics TTM CFF year-on-year change?
What is iTeos Therapeutics annual cash flow from financing activities?
The current annual CFF of ITOS is $122.24 M
What is the all time high annual CFF for iTeos Therapeutics?
iTeos Therapeutics all-time high annual cash flow from financing activities is $340.34 M
What is iTeos Therapeutics annual CFF year-on-year change?
Over the past year, ITOS annual cash flow from financing activities has changed by +$121.13 M (+10883.02%)
What is iTeos Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ITOS is $285.00 K
What is the all time high quarterly CFF for iTeos Therapeutics?
iTeos Therapeutics all-time high quarterly cash flow from financing activities is $212.87 M
What is iTeos Therapeutics quarterly CFF year-on-year change?
Over the past year, ITOS quarterly cash flow from financing activities has changed by +$727.00 K (+164.48%)
What is iTeos Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ITOS is $122.24 M
What is the all time high TTM CFF for iTeos Therapeutics?
iTeos Therapeutics all-time high TTM cash flow from financing activities is $340.34 M
What is iTeos Therapeutics TTM CFF year-on-year change?
Over the past year, ITOS TTM cash flow from financing activities has changed by -$22.00 K (-0.02%)